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Abstract: Neurodegenerative diseases have a complex nature which highlights the need for mul-
titarget ligands to address the complementary pathways involved in these diseases. Over the
last decade, many innovative curcumin-based compounds have been designed and synthesized,
searching for new derivatives having anti-amyloidogenic, inhibitory of tau formation, as well as
anti-neuroinflammation, antioxidative, and AChE inhibitory activities. Regarding our experience
studying 3-substituted coumarins with interesting properties for neurodegenerative diseases, our
aim was to synthesize a new series of curcumin–coumarin hybrid analogues and evaluate their
activity. Most of the 3-(7-phenyl-3,5-dioxohepta-1,6-dien-1-yl)coumarin derivatives 11–18 resulted
in moderated inhibitors of hMAO isoforms and AChE and BuChE activity. Some of them are also
capable of scavenger the free radical DPPH. Furthermore, compounds 14 and 16 showed neuropro-
tective activity against H2O2 in SH-SY5Y cell line. Nanoparticles formulation of these derivatives
improved this property increasing the neuroprotective activity to the nanomolar range. Results
suggest that by modulating the substitution pattern on both coumarin moiety and phenyl ring,
ChE and MAO-targeted derivatives or derivatives with activity in cell-based phenotypic assays can
be obtained.
Keywords: curcumin; curcumin–coumarin hybrids; neuroprotection; monoamine oxidase inhibition;
cholinesterase inhibition; scavenging activity
1. Introduction
In neurodegenerative diseases, a loss of nerve cells is observed in the brain and spinal
cord, leading to sensory dysfunction (dementia) or loss of function (ataxia). Mitochondrial
dysfunction, oxidative stress, protein misfolding, neuroinflammation, and finally apoptosis
have been recognized by different studies as pathological causes of neurodegenerative dis-
eases such as Parkinson’s disease (PD), Alzheimer’s disease (AD), sclerosis multiple (MS),
and amyotrophic lateral sclerosis (ALS). Currently, commercially available and approved
drugs for these disorders only temporarily relieve symptoms but do not significantly alter
disease progression. The development of new treatment strategies remains in the preclini-
cal and clinical stages. Due to the complex nature of neurodegenerative diseases, it seems
necessary to design multitarget ligands to address the complementary pathways involved
in these diseases [1,2].
Curcumin is a dietary polyphenol presented in the curry spice turmeric. Numerous
studies describe its therapeutic potential for neurodegenerative diseases, including AD and
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PD, due to its powerful antioxidant, anti-protein aggregation, and anti-inflammatory prop-
erties [3,4]. However, curcumin exhibits instability, poor bioavailability, and low cellular
uptake, which limits the interest of its use in these disorders [5]. To address this problem,
new nanoformulations such as liposomes, solid-lipid nanoparticles, micelles, polymer
nanoparticles, and polymer conjugates have been developed [6,7]. With the same objective
and also to improve its activity, in recent years, many compounds derived from curcumin
have been designed and synthesized. Some of them have shown anti-amyloidogenic activ-
ity, inhibitory of the formation of tau, as well as anti-neuroinflammatory, antioxidant, and
inhibitory of acetylcholinesterase (AChE) [8,9].
Coumarins are natural or synthetic compounds with diverse biological activities.
Many synthetic coumarin derivatives have been designed to obtain new drugs with poten-
tial activity in neurodegenerative diseases. Coumarin moiety has the potential to achieve
monoamine oxidase (MAO) inhibitory activity (e.g., MAO-A and MAO-B inhibitors),
AChE, β- and γ-secretase inhibition. Some of these compounds display potent antioxidant
activity and, therefore, could protect cells from neurodegeneration [10]. In the last few
years, our group has described different series of 3-substituted coumarins displaying these
properties [11–17].
MAO inhibition by coumarins may also prevent oxidative stress, through inhibition of
neurotransmitters degradation, leading a neuroprotective effect. It has been described that
systemic injection of a MAO inhibitor decreases 6-hydroxydopamine-induced oxidative
stress [18].
Considering the above described and with the aim to improve the properties of
curcumin and coumarin for the treatment of neurodegenerative diseases such as AD or
PD, we have synthesized a series of curcumin–coumarin hybrid analogues (Figure 1) to
study their activity as MAO and AChE inhibitors, free radical scavengers as well as their
neuroprotective activity against hydrogen peroxide (H2O2). In addition, to facilitate their
passage through cell membranes and therefore improve their neuroprotective activity,
some of the derivatives have been formulated into nanoparticles.
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2. Results
2.1. Synthesis of Coumarins 5 and 9
For the synthesis of coumarin 5, firstly, pyrogallol was treated with K2CO3 and
dichlorodiphenylmethane in CH3CN, obtaining a protected catechol 2. In a second
step, the protected catechol was reacted with magnesium chloride, triethylamine, and
para-formaldehyde to afford the protected ortho-hydroxybenzaldehyde 3. Then, ortho-
hydroxybenzaldehyde 3 was reacted with s dium hydride and (trimethylsilyl)propioloyl
chlori to obtain th silylated ester 4. Silylated este 4 was reacted with 1,4-dizabicyclo
[2.2.2]octane (DABCO) in THF und r r flux, resulting in he desired coum rin 5 (Scheme 1).
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e 1. (a) dichl rodiphenylmethane, (Ph)2O, 18 ◦C, 30 min; (b) MgCl2, Et3N, (CH2O)n, THF reflux,
4 h; (c) (trimethylsilyl)propioloyl chloride, NaH, THF, reflux, 10 h; (d) DABCO, THF, reflux, 12 h.
Coumarin 9 was synthesized from 2,4,5-trihydroxybenzaldehyde (6) following a
similar procedure to that described above (Scheme 1).
2.2. Synthesis of a Series of Curcumin–Coumarin Hybrid Analogues 11–18
These compounds were obtained through direct coupling of an acethylacetone–B2O3
complex with the corresponding formylcoumarin previously obtained (5 or 9) and the ade-
quate s bstituted benzaldehyde (10a–d) in the presence of tributyl borate and n-butylamine
(Scheme 2). The deprotection of the phenol groups was carried out in two steps, firstly
acidium medium was used to hydrolyze tris(methoxymethoxy) groups (OMOM) followed
by hydrolysis of the diphenylbenzodioxole group to obtain compounds 11–18. Com-
pounds 11–18 were stored at −20 ◦C and in the dark.





















Compound  hAChE % Inh 100 μM  hBuChE % Inh 100 μM  hMAO‐A % Inh 100 μM  hMAO‐B % Inh 100 μM 
11  2.96% ± 0.10%  2.90% ± 0.10%  nd  nd 
12  5.70% ± 0.40%  43.26% ± 2.90%  60.91% ± 4.09%  45.76% ± 3.07% 
13  38.47% ± 2.58%  36.08% ± 2.42%  nd  nd 
14  5.62% ± 0.40%  8.69% ± 0.60%  54.33% ± 3.64%  45,81% ± 3,07% 
15  47.69% ± 3.20%  50.94% ± 3.41%  nd  nd 
16  17.33% ± 1.16%  21.37% ± 1.43%  58.18% ± 3.90%  78.93% ± 5.59% 
17  42.88% ± 2.87%  46.63% ± 3.12%  nd  nd 
18  5.14% ± 0.34%  10.38% ± 0.70%  51.50% ± 3.45%  55.72% ± 3.74% 
Curcumin  64.83% ± 4.34%  35.46% ± 2.38%  84.20% ± 5.61%  92.60% ± 6.17% 
Results are expressed as the mean ± e.e.m (n = 3). nd: not determined. At concentration > 100 μM, compounds precipitate. 
   
c e e 2. (a) i: 2,4-Pentanedione, B2O3, EtOAc, 40 ◦C, 2 h; (BuO)3B; nBuNH2, EtOAc, 25–40 ◦C 22 h;
ii: HCl, 60 ◦C, 1 h; iii: H2, Pd/C, EtOH, rt, 48 h.
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2.3. Nanoparticles Formulations
Curcumin and curcumin–coumarin hybrid analogue loaded PLGA nanoparticles were
prepared by an interfacial deposition method. All nanoparticles showed a narrow size
distribution with mean diameters between 141–168 nm and PDI of 0.121–0.153, and a Zeta
potential of −20 to −26 mV (dispersed in purified water). The encapsulation efficiency
was similar for all the drugs assayed, obtaining percentages of encapsulation of 56, 53, and
55% for curcumin and curcumin–coumarin hybrid analogues 14 and 16, respectively.
2.4. In Vitro Activity
2.4.1. Cholinesterase Inhibition
As seen in Table 1, compounds 15 and 17 at 100 µM concentration inhibit the activity
of both AChE and butyrylcholinesterase (BuChE) by approximately 50%. Therefore, their
activity is lower than that presented by curcumin on AChE. Compound 12 resulted in the
most selective derivative with activity only on BuChE.
Table 1. Percentage inhibition of human cholinesterases (hAChE and hBuChE) and human monoamine oxidases (hMAO-A
and hMAO-B).
Compound hAChE % Inh 100 µM hBuChE % Inh 100 µM hMAO-A % Inh 100 µM hMAO-B % Inh 100 µM
11 2.96% ± 0.10% 2.90% ± 0.10% nd nd
12 5.70% ± 0.40% 43.26% ± 2.90% 60.91% ± 4.09% 45.76% ± 3.07%
13 38.47% ± 2.58% 36.08% ± 2.42% nd nd
14 5.62% ± 0.40% 8.69% ± 0.60% 54.33% ± 3.64% 45.81% ± 3.07%
15 47.69% ± 3.20% 50.94% ± 3.41% nd nd
16 17.33% ± 1.16% 21.37% ± 1.43% 58.18% ± 3.90% 78.93% ± 5.59%
17 42.88% ± 2.87% 46.63% ± 3.12% nd nd
18 5.14% ± 0.34% 10.38% ± 0.70% 51.50% ± 3.45% 55.72% ± 3.74%
Curcumin 64.83% ± 4.34% 35.46% ± 2.38% 84.20% ± 5.61% 92.60% ± 6.17%
Results are expressed as the mean ± e.e.m (n = 3). nd: not determined. At concentration > 100 µM, compounds precipitate.
2.4.2. Monoamine Oxidase Inhibition
Most of the curcumin–coumarin hybrid analogues herein evaluated were not selective,
inhibiting both MAO isoforms in a similar percentage (Table 1). The most potent inhibitor was
compound 16 with IC50 (hMAO-B) = 26.18± 1.76 µM, which also exhibited greater selectivity
over MAO-B. In any case, its inhibitory activity turned out to be lower than that shown by
curcumin: IC50 (hMAO-A) = 10.18 ± 0.68 µM and IC50 (hMAO-B) = 1.78 ± 0.12 µM. For
compounds 11, 13, 15, 17, their activity on the MAO isoforms could not be determined
because they react with the Amplex Red reagent.
2.4.3. Scavenging Activity
As seen in Figure 2, most of the curcumin–coumarin hybrid analogues 11–18 showed
moderate activity as free radical scavengers. All of them resulted less active than curcumine
or vitamin C. In general, among the curcumin–coumarin hybrid analogues, the compounds
with the highest activity are those with three hydroxyl groups in contiguous positions of
the phenyl substituent. Compounds 11, 15, and 16 that did not present this characteristic
resulted in being the least active.
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Figure 2. Percenta f neutralization of radical DPPH. by curcumin, curcumin–coumarin hybrid
analogues 1–18 (1 µ ) and vitamin C used as referenc (100 µM). Each v lue is the mean ± s.e.m.
of 3 experiments ( ).
2.4.4. Neuroprotective Activity against H2O2
The neuroprotective activity of these curcumin–coumarin hybrid analogues 11–18 was
evaluated in two different cell models, primary culture of rat motor cortex neurons and
SH-SY5Y cell line. Neither curcumin nor any of the cu cumin–couma in hybrid analogues
s 11–18 (10 µM) show d a protective effect against hydr gen peroxide (H2O2) in the primary
c lture of rat motor cortex (data not shown). However, 14 and 16 showed a significant
increase of viability on the SH-SY5Y cell line treated with H2O2 (Figure 3). Because
of this neuroprotective effect, compounds 14 and 16 were formulated in biodegradable
nanoparticles, and their neuroprotective activity against H2O2 was also evaluated in the
SH-SY5Y cell line. In this formulation, derivatives 14 and 16 at low concentration (10 nM)
presented a statistically significant neuroprotective activity. As can be seen in Figure 4, the
activity of compound 16 turned from a neurotoxic effect when the cultures were treated at
1 µM concentration to a neuroprotective eff ct at 10 nM concentration.
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hybrid analogues 11–18, were obtained  in  low yields  (5% approximately). This can be 
probably explained due to the low reactivity of the carbonyl of the formyl group at posi‐
tion 3 of coumarins. This fact was corroborated when obtaining in the same reaction the 
corresponding  1,7‐biscoumarin‐3,5‐dioxohepta‐1,6‐dienyl derivatives  in very  low yield 
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Figure 3. Neuroprotective effects of curcumin and curcumin–coumarin hybrid analogues 11–18
(10 µM) on SH-SY5Y cells. Th results are expressed as % viability versus the control group (t
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probably explained due to the low reactivity of the carbonyl of the formyl group at posi‐
tion 3 of coumarins. This fact was corroborated when obtaining in the same reaction the 
corresponding  1,7‐biscoumarin‐3,5‐dioxohepta‐1,6‐dienyl derivatives  in very  low yield 
(data not shown). Furthermore, in the same reaction, we appreciated the formation of the 
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3. Discussion
Coumarins 5 and 9 were obtained by a similar route based on reactions described in
the literature and both in good yield (68.3% and 81.3%, respectively). However, 3-(7-phenyl-
3,5-dioxohepta-1,6-dien-1-yl)coumarin derivatives, namely as curcumin–coumarin hybrid
analogues 11–18, were obtained in low yields (5% approximately). This can be probably
explained due to the low reactivity of th carbonyl of the formyl group at positio 3 of
coumarins. This fact was corr borated when obtaining in the same reaction the corre-
sponding 1,7-biscoumarin-3,5-dioxohepta-1,6-dienyl derivatives in very low yield (data not
shown). Furthermore, in the same reaction, we appreciated the formation of the correspond-
ing 1,7-bisphenyl-3,5-dioxohepta-1,6-dienyl derivatives, previously described [19–22], and
obtained in higher yields than the curcumin–coumarin hybrid analogues 11–18. Despite
the poor yield for curcumin–coumarin hybrid 11–18, th y could be easily detected and
isolated because of their red color.
Regarding curcumin, the curcumin–coumarin hybrid analogues 11–18 conserve two
aromatic systems in their structure, replacing a phenyl ring with a coumarin and maintain
the length and flexibility of the central link region. These characteristics have been identified
as a key for the derivatives to maintain the interest of curcumin in neurodegenerative
diseases [23]. Additionally, different substitution partners on both aromatic systems,
coumarin moiety, and phenyl ring have been studied.
MAO plays an important role in the homeostasis of neurotransmitters in the brain.
MAO-B inhibitors are being used in combination with L-dopa to manage PD. However,
the beneficial effects of MAO-B inhibitors in PD are not only associated with maintaining
dopamine levels but also with their neuroprotective properties [24]. The occurrence of
activated MAO-B in the brains of patients with AD has also been evidenced. Furthermore,
MAO-A has a different appearance in different parts of the brains of patients with AD.
MAO-A is increased in the hypothalamus and frontal pole, revealing that activated MAO-A
in neurons is involved in the pathology of this disease as a predisposing factor. In addition,
increased MAO-A activity appears more significant in the glia of patients with AD [25].
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The above described demonstrates the interest in MAO inhibitors for the treatment of these
diseases. Compounds 12, 14, 16, and 18 showed moderate inhibitory activity on both MAO
isoforms (Table 1). Hydroxyl substituents at positions 6 and 7 of the coumarin nucleus
(compounds 16 and 18) afforded more potent derivatives on the MAO-B isoform than
substitution at positions 7 and 8 (compounds 12 and 14). However, the position of the
hydroxyl groups on the phenyl ring does not appear to significatively modify the activity of
these compounds on MAO-B. The opposite behavior is observed in the activity of MAO-A.
Compounds 12 and 16 resulted in the most potent derivatives, both bearing hydroxyl
groups at positions 4, 6, and 7 of the phenyl ring. Only compound 16 exhibited moderate
MAO-B selectivity [selectivity index (SI) = IC50 hMAO-A/IC50 hMAO-B; SI = 3.82].
Acetylcholine levels are regulated mainly by AChE but also by BuChE. Role of BuChE
is less important than AChE in healthy brains. However, the AChE activity remains
unchanged or even decreases in AD, while BuChE progressively increases, suggesting that
inhibition of both enzymes may be considered a valid approach for AD therapy, increasing
levels of AChE [26]. Curcumin–coumarin hybrid analogues 13, 15, and 17 showed similar
activity on both AChE and BuChE, while compound 12 resulted in selectively inhibiting
BuChE activity (Table 1).
Among the studied curcumin–coumarin hybrid analogues, only compound 12 showed
potential to inhibit both degradation of acetylcholine (via BuChE inhibition) and monoamines
(via non-selective MAO inhibition) (Table 1).
Curcumin can protect neurons against inflammation, oxidative stress, apoptosis, or
mitochondrial dysfunction [27,28]. It has been described that curcumin concentrations up
to 20 µM increase viability in different cell models treated with H2O2 [29]. However, the
effect of curcumin on SH-SY5Y cells is both dose and time-dependent. Approximately
40 µM concentration and 24 h exposure are the critical parameters at which the cell viability
significantly decreases [30]. Other authors describe even lower concentrations (10 µM)
to decreases SH-SY5Y proliferation and 20 µM to cause apoptosis [31]. Considering the
controversies found in the literature, we studied the neuroprotective effects of low con-
centrations (≤10 µM) of curcumin and curcumin–coumarin hybrid analogues on two
different neuronal models, primary culture of rat motor cortex neurons and SH-SY5Y
cell line. While neither of the curcumin–coumarin hybrid analogues 11–18 nor curcumin
protected rat motor cortex neurons against H2O2 (data not shown), compounds 14 and 16
showed neuroprotective effects at 10 µM concentration on SH-SY5Y cells (Figure 3). Com-
pound 14 also showed scavenger activity (Figure 2) which could justify, at least partially,
its neuroprotective activity. However, compound 16 lacks this activity, but it is the most
potent MAO-B inhibitor, indicating that different mechanisms may be implicated in this
neuroprotective activity.
Based on the statistically significant increase in viability on SH-SY5Y cells treated with
H2O2 produced by compounds 14 and 16 at 10 µM concentration, both compounds were
formulated in biodegradable nanoparticles. This formulation improves the neuroprotective
effect at 10 nM concentration on SH-SY5Y cells treated with H2O2 (Figure 4). Furthermore,
compound 16 formulated in nanoparticles goes from having a neurotoxic effect at 1 µM
concentration to a statistically significant neuroprotective effect at 10 nM concentration. To
explain this neuroprotective effect, it is necessary to resort to the hormesis, which is shared
by several phytochemical compounds, including curcumin [32]. Hormesis is defined as
a stimulation of cellular protection at low doses while it is inhibited at high doses of the
compound, resulting in an inverted J or U-shaped dose-response curve as it can be obtained
for compounds 14 and 16. However, at concentrations used in this work, neuroprotective
activity was not found for coumarin.
4. Materials and Methods
4.1. Materials and Instrumentation
All reactions utilizing air- or moisture-sensitive reagents were carried out in flame-
dried glassware under an argon atmosphere, unless otherwise stated. Hexane, CH2Cl2,
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THF, Et2O, Et3N, and n-BuNH2 were distilled prior to use according to the standard
protocols. Other reagents were purchased and used as received without further purification
unless otherwise stated. Reactions were magnetically stirred and monitored by thin-layer
chromatography (TLC). Analytical TLC was performed on plates precoated with silica
gel (Merck 60 F254, 0.25 mm). Compounds were visualized with UV light and/or by
staining with ethanolic phosphomolybdic acid (PMA) followed by heating on a hot plate.
Flash chromatography (FC) was performed with silica gel (35–60 mesh) under pressure.
Melting points were determined in a Reichert Kofler thermopan or in capillary tubes in a
Buchi 510 apparatus and are uncorrected. NMR spectra were recorded on Bruker AMX
250 (1H, 250 MHz; 13C, 62.9 MHz) spectrometer in CDCl3 or DMSO-d6 with TMS as the
internal standard. Chemical shifts (δ) are given in ppm and coupling constants (J) in Hz.
Multiplicity is indicated as follows: s, singlet; d, doublet; m, multiplet; bs, broad singlet.
Elemental analyses were performed on Thermo-Finnigan Flash 1112 CHNS/O analyzer
(Supplementary Materials).
4.2. Chemical Synthesis
4.2.1. Synthesis of 2,2-Diphenylbenzo[1,3]dioxol-4-ol (2)
Dichlorodiphenylmethane (9.65 mL, 50.31 mmol) was added to a stirred mixture of
pyrogallol (1, 4.23 g, 33.54 mmol) in diphenyl ether (25 mL), and the reaction mixture was
heated at 180 ◦C for 30 min. The mixture was cooled to room temperature, and petroleum
ether (50 mL) was added to give a solid compound [33,34]. Then the solid was filtered
and purified by column chromatography using CH2Cl2 to yield 2 as a white solid (9.65 g,
99.2%). m.p.: 165 ◦C. 1H-NMR (250 MHz, CDCl3, δ ppm): 7.54 (4H, m), 7.37 (6H, m), 6.71
(1H, t, J = 6.7 Hz), 6.53 (1H, d, J = 6.4 Hz), 6.46 (1H, d, J = 6.4 Hz), 4.98 (1H, br). 13C-NMR
(62.9 MHz, CDCl3, δ ppm): 148.2, 139.9, 139.3, 133.8, 129.1 (2C), 128.2 (4C), 126.3 (4C), 122.1,
116.1, 110.8, 101.9. Anal. Calcd. (%) for [C19H14O3]: C, 78.61; H, 4.86; found (%): C, 78.58;
H, 4.83.
4.2.2. Synthesis of 4-Hydroxy-2,2-diphenylbenzo[1,3]dioxol-5-carbaldehyde (3)
To a dry THF solution (300 mL) of the 2,2-diphenylbenzo[1,3]dioxol-4-ol (2) (6.2 g,
21.35 mmol), anhydrous magnesium chloride (4.065 g, 42.70 mmol), triethylamine (5.95 mL,
4.32 g, 42.70 mmol) and paraformaldehyde (1.923 g, 64.05 mmol) were added. The reaction
mixture was heated to reflux under Ar atmosphere for 4 h, and monitored by TLC (hex-
ane:ethyl acetate = 8:2). After complete consumption of the phenol, the reaction mixture
was cooled and diluted with diethyl ether (100 mL). The organic layer was washed succes-
sively with HCl (1 M, 2 × 100 mL) and H2O (2 × 100 mL), and then dried (Na2SO4) [35].
The product was purified by column chromatography using hexane:ethyl acetate (98:2) to
yield 3 as a white solid (5.6 g, 82.5%). m.p.: 159 ◦C. 1H-NMR (250 MHz, CDCl3, δ ppm):
11.07 (1H, bs), 9.68 (1H, s), 7.59 (4H, m), 7.38 (6H, m), 7.12 (1H, d, J = 8.2 Hz), 6.62 (1H, d,
J = 8.2 Hz). 13C-NMR (62.9 MHz, CDCl3, δ ppm): 194.9, 154.2, 145.3, 139.1 (2C), 133.6, 130.2,
129.3 (2C), 128.2 (4C), 126.0 (4C), 119.2, 118.09, 101.9. Anal. Calcd. (%) for [C20H14O4]: C,
75.46; H, 4.43; found (%): C, 75.44; H, 4.40.
4.2.3. Synthesis of 5-Formyl-2,2-diphenylbenzo[1,3]dioxol-4-yle (trimethylsilyl)propiolate (4)
Sodium hydride (0.942 g, 23.55 mmol, 60%, washed with hexane) was suspended
in anhydrous THF (25 mL), then cooled to 0 ◦C. A solution of 3 (2.50 g, 7.85 mmol) in
anhydrous THF (25 mL) was dropwise added and the suspension was stirring for 1 h. Then,
trimethylsilylpropioloyl chloride (3.78 g, 23.55 mmol) [36] in THF (10 mL) was dropwise
added. The mixture was refluxed for 10 h. The mixture was quenched with ice-cold
water and extracted three times with EtOAc. The combined organic layers were washed
with brine, dried over Na2SO4, and evaporated [37]. The residue was purified by column
chromatography on SiO2 hexane:ethyl acetate (2:98) to obtain silylated ester 4 as a colorless
syrup (2.8 g, 80.7%). 1H-NMR (250 MHz, CDCl3, δ ppm): 9.93 (1H, s), 7.53 (4H, m), 7.39
(7H, m), 6.87 (1H, d, J = 8.2 Hz), 0.27 (9H, s). 13C-NMR (62.9 MHz, CDCl3, δ ppm): 186.8,
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153.6, 149.1, 145.6, 139.5, 138.4 (2C), 129.5 (2C), 128.2 (4C), 127.1, 126.2 (4C), 123.5, 120.3,
106.8, 98.1, 92.8, −1.1. Anal. Calcd. (%) for [C26H22O5Si]: C, 70.57; H, 5.01; found (%): C,
70.56; H, 5.00.
4.2.4. Synthesis of 2′,2′-Diphenyl-1,3-dioxol[h]coumarin-3-carbaldehyde (5)
A mixture of silylated ester 4 (2.8 g, 6.33 mmol), and DABCO (1.42 g, 12.66 mmol) in
THF (150 mL) was refluxed under Ar atmosphere. After 12 h, the mixture was diluted with
CH2Cl2, washed with HCl (10%) and brine, and dried over Na2SO4 [38]. The solvent was
evaporated to leave a residue, which was purified by silica-gel chromatography (CH2Cl2)
to afford the 3-formylcoumarin 5 as a yellow solid (1.6 g, 68.3%). m.p.: 181 ◦C. 1H-NMR
(250 MHz, CDCl3, δ ppm): 10.18 (1H, s), 8.31 (1H, s), 7.59 (4H, m), 7.40 (6H, m), 7.23 (1H,
d, J = 8.3 Hz), 6.94 (1H, d, J = 8.3 Hz). 13C-NMR (62.9 MHz, CDCl3, δ ppm): 187.4, 159.3,
153.7, 146.2, 139.0, 138.6 (2C), 133.5, 129.6 (2C), 128.4 (4C), 126.4, 126.0 (4C), 120.6, 118.5,
114.3, 107.0. Anal. Calcd. (%) for [C23H14O5]: C, 74.59; H, 3.81; found (%): C, 74.56; H, 3.80.
4.2.5. Synthesis of 6-Hydroxy-2,2-diphenylbenzo[1,3]dioxol-5-carbaldehyde (7)
Following the procedure previously described to obtain compound 2, dichlorodiphenyl-
methane (7.4 mL, 38.92 mmol) was reacted with 6 (4.0 g, 25.95 mmol) in diphenyl ether
(25 mL), to yield 7 as a white solid (8.0 g, 96.8% yield) [33,39]. m.p.: 128 ◦C. 1H-NMR
(250 MHz, CDCl3, δ ppm): 11.79 (1H, br), 9.59 (1H, s), 7.58 (4H, m), 7.39 (6H, m), 6.90
(1H, s), 6.55 (1H, s). 13C-NMR (62.9 MHz, CDCl3, δ ppm): 193.6, 161.4 (2C), 154.6, 141.0,
139.1 (2C), 129.4 (2C), 128.3 (4C), 126.1 (2C), 126.0 (2C), 109.4, 98.4, 90.1. Anal. Calcd. (%)
for [C20H14O4]: C, 75.46; H, 4.43; found (%): C, 75.42; H, 4.42.
4.2.6. Synthesis of 6-Formyl-2,2-diphenylbenzo[1,3]dioxol-5-yle(trimethylsilyl)propiolate (8)
Following the procedure previously described to obtain compound 4, compound 7
(2.5 g, 7.85 mmol) was reacted with sodium hydride (0.942 g, 23.55 mmol, 60%, washed
with hexane), and trimethylsilylpropioloyl chloride (3.78 g, 23.55 mmol) [36] to obtain 8 as
a colorless syrup (2.5 g, 72.0%) [37]. 1H-NMR (250 MHz, CDCl3, δ ppm): 9.96 (1H, s), 7.50
(5H, m), 7.34 (6H, m), 6.91 (1H, s), 0.20 (9H, s). 13C-NMR (62.9 MHz, CDCl3, δ ppm): 187.0,
154.3, 151.0, 145.9, 140.9, 138.2 (2C), 129.2 (2C), 128.4 (4C), 126.9 (4C), 125.8, 122.5, 118.2,
107.1, 97.9, 85.8. Anal. Calcd. (%) for [C26H22O5Si]: C, 70.57; H, 5.01; found (%): C, 70.55;
H, 4.99.
4.2.7. Synthesis of 2′,2′-Diphenyl-1,3-dioxol[g]coumarin-3-carbaldehyde (9)
Following the procedure previously described to obtain compound 5, a mixture of
the propionic ester 8 (2.5 g, 5.65 mmol), and DABCO (1.26 g, 11.30 mmol) afforded the
3-formylcoumarin 9 as a yellow solid (1.7 g, 81.3%) [38]. m.p.: 173 ◦C. 1H-NMR (250 MHz,
CDCl3, δ ppm): 9.97 (1H, s), 8.12 (1H, s), 7.44 (4H, m), 7.38 (6H, m), 6.92 (1H, s), 6.69 (1H, s).
13C-NMR (62.9 MHz, CDCl3, δ ppm): 191.8, 160.6, 152.1, 151.2, 145.3, 143.5, 138.9 (2C), 129.5
(2C), 128.4 (4C), 126.0 (4C), 122.4, 119.2, 108.3, 103.8, 98.4. Anal. Calcd. (%) for [C23H14O5]:
C, 74.59; H, 3.81; found (%): C, 74.55; H, 3.79.
4.2.8. Synthesis of 7,8-Dihydroxy-3-(7-(2′,4′,6′-trihydroxyphenyl)-3,5-dioxohepta-1,6-dien-
1-yl)coumarin (11)
2,4-Pentanedione (0.25 g, 2.5 mmol) and boric anhydride (0.121 g, 1.75 mmol) were
dissolved in EtOAc (5 mL) and stirred for 2 h at 40 ◦C. Coumarin 5 (0.925 g, 2.5 mmol),
tris(methoxymethoxy)benzaldehyde 10a [40,41] (0.715 g, 2.5 mmol) and tributyl borate
(2.3 g, 10 mmol) were added and the reaction mixture was stirred for 0.5 h. Then a solution
of n-butylamine (0.182 g, 2.5 mmol) in EtOAc (2.5 mL) was dropwise added over a period
of 30 min, the mixture was stirred for a further 18 h at room temperature and 4 h at 40 ◦C.
The mixture was hydrolyzed by the addition of 0.4 N HCl (10 mL) and heating to 60 ◦C for
1 h. The organic layer was separated, and the aqueous layer was extracted three times with
EtOAc. The combined organic layers were washed with water and dried over Na2SO4.
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Evaporation of the solvent left a red-brown powder [42]. The solid was dissolved in 80 mL
of ethanol and treated with 10% Pd/C (0.6 g, 33 wt. % of starting material) [43]. The system
was purged several times with hydrogen and stirred under hydrogen for 48 h. The reaction
mixture was then purged with Ar and filtered through Celite washing with CH3OH. The
filtrate was evaporated and the dark red solid was purified by column chromatography
using CH2Cl2:CH3OH (9:1 and 8:2) to give 11 (44 mg, 4.15%). m.p.: 180 ◦C (dec.). 1H-NMR
(250 MHz, DMSO-d6, δ ppm): 10.10 (2H, bs), 9.70 (2H, bs), 9.51 (2H, bs), 7.72 (1H, s), 7.46
(1H, d, J = 15.5 Hz), 7.15 (1H, d, J = 8.8 Hz), 6.84 (1H, d, J = 15.4 Hz), 6.64 (3H, m), 5.96
(2H, s), 5.83 (1H, s). 13C-NMR (62.9 MHz, DMSO-d6, δ ppm): 182.4, 169.7, 160.5, 158.7 (2C),
158.0, 148.7, 141.6, 139.5, 137.6, 134.0, 130.5, 126.9, 125.3, 120.7, 120.6, 114.3, 114.2, 109.9,
103.1, 95.7 (2C). Anal. Calcd. (%) for [C22H16O9]: C, 62.27; H, 3.80; found (%): C, 62.24;
H, 3.78.
4.2.9. Synthesis of 7,8-Dihydroxy-3-(7-(2′,4′,5′-trihydroxyphenyl)-3,5-dioxohepta-1,6-dien-
1-yl)coumarin (12)
Following the procedure described above to obtain compound 11, reaction of coumarin
5 (0.925 g, 2.5 mmol) and tris(methoxymethoxy)benzaldehyde 10b [44] (0.715 g, 2.5 mmol)
yielded compound 12 as a red solid (40 mg, 3.77%). m.p.: 177 ◦C (dec.). 1H-NMR (250 MHz,
DMSO-d6, δ ppm): 10.12 (2H, bs), 9.76 (2H, bs), 9.50 (2H, bs), 7.79 (1H, d, J = 16.1 Hz), 7.65
(1H, s), 7.07 (1H, d, J = 8.8 Hz), 6.78 (1H, d, J = 15.4 Hz), 6.65 (1H, d, J = 16.1 Hz), 6.59
(2H, m), 6.42 (1H, s), 6.19 (1H, s), 5.83 (1H, s). 13C-NMR (62.9 MHz, DMSO-d6, δ ppm):
187.4, 179.5, 162.9, 152.5, 148.7, 148.6, 141.6, 140.4, 139.5, 137.6, 134.0, 129.0, 126.9, 124.2,
120.7, 120.6, 115.6, 114.4, 114.3, 114.2, 103.5, 96.9. Anal. Calcd. (%) for [C22H16O9]: C, 62.27;
H, 3.80; found (%): C, 62.22; H, 3.77.
4.2.10. Synthesis of 7,8-Dihydroxy-3-(7-(2′,3′,4′-trihydroxyphenyl)-3,5-dioxohepta-1,6-
dien-1-yl)coumarin (13)
Following the procedure described above to obtain compound 11, reaction of coumarin
5 (0.925 g, 2.5 mmol) and tris(methoxytrimethoxy)benzaldehyde 10c [45,46] (0.715 g,
2.5 mmol) yielded compound 13 as a red solid (46 mg, 4.34%). m.p.: 185 ◦C (dec.). 1H-
NMR (250 MHz, DMSO-d6, δ ppm): 10.10 (2H, bs), 9.74 (2H, bs), 9.52 (2H, bs), 7.79 (1H,
d, J = 16.0 Hz), 7.72 (1H, s), 7.08 (1H, d, J = 8.8 Hz), 6.86 (1H, d, J = 15.8 Hz), 6.78 (1H, d,
J = 16.1 Hz), 6.58 (2H, m), 6.51 (1H, d, J = 8.4 Hz), 6.12 (1H, d, J = 8.4 Hz), 5.78 (1H, s).
13C-NMR (62.9 MHz, DMSO-d6, δ ppm): 184.6, 162.4, 158.9, 148.8, 148.7, 147.4, 141.6, 139.5,
137.6, 134.0, 133.8, 128.4, 126.9, 124.4, 120.8, 120.7, 120.6, 114.7, 114.3, 114.2, 107.8, 101.6.
Anal. Calcd. (%) for [C22H16O9]: C, 62.27; H, 3.80; found (%): C, 62.26; H, 3.79.
4.2.11. Synthesis of 7,8-Dihydroxy-3-(7-(3′,4′,5′-trihydroxyphenyl)-3,5-dioxohepta-1,6-
dien-1-yl)coumarin (14)
Following the procedure described above to obtain compound 11, reaction of coumarin
5 (0.925 g, 2.5 mmol) and tris(methoxymethoxy)benzaldehyde 10d [47–49] (0.715 g, 2.5 mmol)
yielded compound 14 as a red solid (48 mg, 4.53%). m.p.: 183 ◦C (dec.). 1H-NMR (250 MHz,
DMSO-d6, δ ppm): 10.09 (2H, bs), 9.70 (2H, bs), 9.53 (2H, bs), 7.70 (2H, m), 7.08 (1H, d,
J = 8.8 Hz), 6.91 (1H, d, J = 16.1 Hz), 6.83 (1H, d, J = 16.1 Hz), 6.74 (1H, d, J = 15.8 Hz), 6.58
(1H, d, J = 8.8 Hz), 6.25 (2H, s), 5.85 (1H, s). 13C-NMR (62.9 MHz, DMSO-d6, δ ppm): 185.8,
180.1, 159.6, 148.7, 146.7 (2C), 141.6, 139.5, 137.6, 135.3, 135.1, 134.0, 128.9, 126.9, 123.0, 120.7,
120.6, 114.3, 114.2, 108.0 (2C), 101.9. Anal. Calcd. (%) for [C22H16O9]: C, 62.27; H, 3.80;
found (%): C, 62.21; H, 3.78.
4.2.12. Synthesis of 6,7-Dihydroxy-3-(7-(2′,4′,6′-trihydroxyphenyl)-3,5-dioxohepta-1,6-
dien-1-yl)coumarin (15)
Following the procedure described above to obtain compound 11, reaction of coumarin
9 (0.925 g, 2.5 mmol) and tris(methoxymethoxy)benzaldehyde 10a (0.715 g, 2.5 mmol)
yielded compound 15 as a red solid (50 mg, 4.72%). m.p.: 179 ◦C (dec). 1H-NMR (250 MHz,
DMSO-d6, δ ppm): 10.09 (2H, bs), 9.75 (2H, bs), 9.51 (2H, bs), 7.77 (1H, d, J = 15.3 Hz), 7.58
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(1H, s), 6.87 (1H, s), 6.75 (1H, d, J = 15.3 Hz), 6.60 (2H, m), 6.45 (1H, s), 5.97 (2H, s), 5.84
(1H, s). 13C-NMR (62.9 MHz, DMSO-d6, δ ppm): 185.2, 180.1, 160.5, 159.4, 158.7 (2C), 148.7,
148.1, 146.3, 139.2, 137.6, 130.5, 126.9, 125.3, 118.8, 113.7, 113.0, 104.9, 103.5, 102.1, 95.7 (2C).
Anal. Calcd. (%) for [C22H16O9]: C, 62.27; H, 3.80; found (%): C, 62.25; H, 3.79.
4.2.13. Synthesis of 6,7-Dihydroxy-3-(7-(2′,4′,5′-trihydroxyphenyl)-3,5-dioxohepta-1,6-
dien-1-yl)coumarin (16)
Following the procedure described above to obtain compound 11, reaction of coumarin
9 (0.925 g, 2.5 mmol) and tris(methoxytrimethoxy)benzaldehyde 10b (0.715 g, 2.5 mmol)
yielded compound 16 as a red solid (53 mg, 5.00%). m.p.: 188 ◦C (dec.). 1H-NMR (250 MHz,
DMSO-d6, δ ppm): 10.10 (2H, bs), 9.76 (2H, bs), 9.55 (2H, bs), 7.75 (1H, d, J = 16.1 Hz),
7.67 (1H, s), 6.95 (1H, d, J = 15.5 Hz), 6.86 (1H, s), 6.68 (1H, d, J = 16.1 Hz), 6.53 (1H,
d, J = 15.5 Hz), 6.38 (1H, s), 6.30 (1H, s), 6.15 (1H, s), 5.84 (1H, s). 13C-NMR (62.9 MHz,
DMSO-d6, δ ppm): 183.8, 181.7, 159.1, 152.5, 148.7, 148.6, 148.1, 146.3, 140.4, 139.7, 137.6,
129.0, 126.9, 124.2, 118.8, 115.6, 114.3, 113.7, 113.0, 103.7, 102.2, 95.4. Anal. Calcd. (%) for
[C22H16O9]: C, 62.27; H, 3.80; found (%): C, 62.20; H, 3.77.
4.2.14. Synthesis of 6,7-Dihydroxy-3-(7-(2′,3′,4′-trihydroxyphenyl)-3,5-dioxohepta-1,6-
dien-1-yl)coumarin (17)
Following the procedure described above to obtain compound 11, reaction of coumarin
9 (0.925 g, 2.5 mmol) and tris(methoxytrimethoxy)benzaldehyde 10c (0.715 g, 2.5 mmol)
yielded compound 17 as a red solid (45 mg, 4.24%). m.p.: 190 ◦C (dec.). 1H-NMR (250 MHz,
DMSO-d6, δ ppm): 10.05 (2H, bs), 9.70 (2H, bs), 9.45 (2H, bs), 7.75 (2H, m), 7.04 (1H, s), 6.95
(1H, d, J = 15.8 Hz), 6.71 (1H, d, J = 15.8 Hz), 6.57 (2H, m), 6.43 (1H, d, J = 8.4 Hz), 6.14
(1H, d, J = 8.4 Hz), 5.85 (1H, s). 13C-NMR (62.9 MHz, DMSO-d6, δ ppm): 186.4, 179.3, 159.0,
148.8, 148.7, 148.1, 147.4, 146.3, 139.2, 137.6, 133.8, 128.4, 126.9, 124.4, 120.8, 118.8, 114.7,
113.7, 113.0, 107.8, 102.1, 96.5. Anal. Calcd. (%) for [C22H16O9]: C, 62.27; H, 3.80; found (%):
C, 62.24; H, 3.73.
4.2.15. Synthesis of 6,7-Dihydroxy-3-(7-(3′,4′,5′-trihydroxyphenyl)-3,5-dioxohepta-1,6-
dien-1-yl)coumarin (18)
Following the procedure described above to obtain compound 11, reaction of coumarin
9 (0.925 g, 2.5 mmol) and tris(methoxytrimethoxy)benzaldehyde 10d (0.715 g, 2.5 mmol)
yielded compound 18 as a red solid (55 mg, 5.19%). m.p.: 185 ◦C (dec.). 1H-NMR (250 MHz,
DMSO-d6, δ ppm): 10.12 (2H, bs), 9.77 (2H, bs), 9.53 (2H, bs), 7.78 (1H, d, J = 15.7 Hz),
7.69 (1H, s), 7.15 (1H, s), 6.94 (1H, d, J = 16.0 Hz), 6.75 (1H, d, J = 16.0 Hz), 6.55 (1H, d,
J = 15.7 Hz), 6.45 (1H, s), 6.25 (2H, s), 5.84 (1H, s). 13C-NMR (62.9 MHz, DMSO-d6, δ ppm):
183.5, 181.8, 158.6, 148.7, 148.1, 146.7 (2C), 146.3, 139.2, 137.6, 135.3, 135.1, 128.9, 126.9, 123.0,
118.8, 113.7, 113.0, 108.0 (2C), 102.0, 94.6. Anal. Calcd. (%) for [C22H16O9]: C, 62.27; H, 3.80;
found (%): C, 62.22; H, 3.73.
4.3. Formulation of Biodegradable Nanoparticles
Resomer® RG503H (Evonic) polymer, which is a 50:50 copolymer of polylactic and
polyglycolic acid in its acid form following the nanoprecipitation technique, was used to
make the biodegradable nanoparticles [50]. Briefly, a 1% aqueous solution of poloxamer
407 (Sigma Aldrich) was used as the aqueous phase. Acetone was used as a solvent for
the polymer and the active principles, the concentration of Resomer® and drug being 0.4%
and 0.1% (p/v), respectively. The organic phase was added slowly at room temperature,
using a syringe, to the aqueous solution, under magnetic stirring. Finally, the acetone
was removed by evaporation at 50 ◦C in a rotary evaporator (Buchi) until a final volume
of 25 mL was obtained. Filtration was performed through 0.22 µm diameter polyamide
membrane filters to remove the non-incorporated drug.
To determine the content of the active principle and the encapsulation efficiency, an
aliquot of the nanosuspensions was diluted in ethanol to dissolve the Resomer® and release
the drugs, determining its concentration by spectrophotometry.
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Size distribution (mean diameter and polydispersity index) and zeta potential of
nanoparticles were determined in purified water at 25 ◦C using a Malvern Zetasizer Nano
ZS instrument (Malvern Instruments Ltd., Malvern, UK).
4.4. Determination of hMAO-A and hMAO-B In Vitro Activity
The in vitro activity of the synthesized curcumin–coumarin hybrid analogues 11–18 or
curcumin on hMAO enzymatic activity was evaluated using an Amplex® Red MAO assay
kit and following a fluorimetric method previously described by us [11]. Briefly, 50 µL of
sodium phosphate buffer (0.05 M, pH 7.4) containing the test molecules (new compounds
or reference inhibitors) in different concentrations and adequate amounts of recombinant
hMAO-A or hMAO-B (adjusted to obtain in our experimental conditions the same reaction
velocity (hMAO-A: 1.1 µg protein; specific activity: 150 nmol of para-tyramine oxidized
to para-hydroxyphenylacetaldehyde/min/mg protein; hMAO-B: 7.5 µg protein; specific
activity: 22 nmol of para-tyramine transformed/min/mg protein)) were incubated for
10 min at 37 ◦C in a flat-black bottom 96-well microtest plate, placed in the dark fluorimeter
chamber. After this incubation period, the reaction was started by adding 50 µL of the
mixture containing (final concentrations) 200 µM of the Amplex® Red reagent, 1 U/mL of
horseradish peroxidase and 1 mM of para-tyramine. The production of H2O2 and, conse-
quently, of resorufin, was quantified at 37 ◦C in a multidetection microplate fluorescence
reader (Fluo-star OptimaTM, BMG LABTECH, Offenburg, Germany) based on the fluo-
rescence generated (excitation, 545 nm, emission, 590 nm) over a 10 min period, in which
the fluorescence increased linearly. Control experiments were carried out simultaneously
by replacing the tested molecules with appropriate dilutions of the vehicles. In addition,
the possible capacity of these molecules to modify the fluorescence generated in the re-
action mixture due to non-enzymatic inhibition (i.e., for directly reacting with Amplex®
Red reagent) was determined by adding these molecules to solutions containing only the
Amplex® Red reagent in sodium phosphate buffer. The specific fluorescence emission (used
to obtain the final results) was calculated after subtraction of the background activity, which
was determined from wells containing all components except the hMAO isoforms, which
were replaced by sodium phosphate buffer solution. The IC50 values for each compound
were calculated by linear regression representing the logarithm of the concentration (M) of
the studied compound (abscissa axis) against the percentage of inhibition of the control
MAO activity (ordinate axis). This linear regression was performed with 4–6 concentrations
of each evaluated compound capable of inhibiting the control enzymatic activity of the
MAO isoenzymes between 20% and 80%.
4.5. Determination of AChE and BuChE In Vitro Activity
Ellman’s method [51] was used to determine in vitro ChE activity. 0.01 U/mL human
recombinant AChE expressed in HEK 293 cells or 0.0005 U/mL BuChE isolated from human
serum were added to a 50 mM phosphate buffer solution (pH 7.2) containing different
concentrations of curcumin–coumarin hybrid analogues 11–18 or curcumin. The mixture
was preincubated at 37 ◦C for 5 min followed by the addition of 5 mM acetylthiocholine or
butyrylthiocholine and 0.25 mM 5,5′-dithio-bis(2-nitrobenzoic acid) (DNTB). The activity
was measured by the absorbance increasing at λ 412 nm at 1 min intervals for 10 min at
37 ◦C (Fluo-Star OptimaTM, BMG LABTECH, Offenburg, Germany). Control experiments
were performed simultaneously by replacing the test drugs with appropriate dilutions
of the vehicles. The specific absorbance (used to obtain the final results) was calculated
after subtraction of the background activity, which was determined in wells containing
all components except the AChE or BuChE, which was replaced by a sodium phosphate
buffer solution.
4.6. DPPH Radical Scavenging Assay
The DPPH was dissolved in methanol (50 µM), and 99 µL of the solution was trans-
ferred to each well of a 96-well microplate. Curcumin–coumarin hybrid analogues 11–18,
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coumarin or reference drug (vitamin C) were added to each well at a final concentration
of 100 µM. Solutions were incubated at room temperature for 30 min. Absorbance was
determined at λ 517 nm using a microplate reader (Fluo-star OptimaTM, BMG LABTECH,
Offenburg, Germany). DPPH radical solution in methanol was used as a control, whereas
a mixture of methanol and sample served as blank. The scavenging activity percent-
age (AA%) was determined according to the equation described by Mensor et al. [52]:
AA% = 100 − ((Abssample − Absblank) × 100/Abscontrol)
4.7. Cell Culture
4.7.1. Primary Culture of Rat Motor Cortex Neurons
Embryos were extracted by cesarean section from 18 days pregnant Wistar Kyoto rats
which were euthanized by CO2 inhalation. Brains were carefully dissected out, and after
removing meninges, a portion of the motor cortex was isolated. Fragments obtained from
several embryos were mechanically digested and cells were resuspended in Neurobasal
medium. The Neurobasal medium was supplemented with 2% B-27 to obtain cortex
neuronal cultures. Cells were seeded in 96-well plates at a density of 200,000 cells/mL.
Cultures were grown for 7–8 days in an incubator (Form Direct Heat CO2, Thermo Electron
Corporation, Madrid, Spain) under saturated humidity at a partial pressure of 5% CO2 in
air at 37 ◦C until a dense neuronal network could be observed [53].
4.7.2. Human Neuroblastoma SH-SY5Y Cell Culture and Maintaining
The SH-SY5Y cells grew in a culture medium containing Ham’s F12 and MEM (mixture
1:1) and supplemented with 15% FBS, 1% L-Glutamine, 1% non-essential amino acids and
1% of penicillin G/streptomycin sulfate (all of them from Sigma-Aldrich S.A.) [54]. The cells
were grown in 75 cm2 flasks in an incubator, under conditions of saturated humidity with
a partial pressure of 5% CO2 in the air, at 37 ◦C. Cell culture medium was replaced every
2 days, and, at 80–90% of confluence, the cells were sub-cultured. To carry out the viability
assays, the cells were seeded in sterile 96-well plates, with a density of 2 × 105 cells/mL
and grown distributed in aliquots of 100 µL for 24 h under the conditions described above.
4.7.3. Cell Viability
Cells grown in 96-well plates were treated with H2O2 (100 µM) and curcumin or test
compounds 11–18 (10 µM). When cells were treated with curcumin or curcumin–coumarin
hybrid analogues 14 and 16 formulated in nanoparticles, they were added in the 24 h prior
to H2O2 treatment. Then, cultures were incubated for 24 h. After this time, cell viability
was determined using MTT (5 mg/mL in Hank’s). 10 µL of MTT solution was added to
each well containing 100 µL of culture medium and the cells were incubated for 2 h as
described above. Then, the culture medium was removed, 100 µL DMSO/well was added
to solve the formazan crystals formed by the viable cells and the absorbance (λ 540 nm)
was quantified in a plate reader. The viability (percentage) was calculated as (Absorbance
(treatment)/Absorbance (negative control))100% [55]. Statistical analysis was performed
using one way ANOVA test followed by Dunnett’s multiple comparison test by using
GraphPad software.
5. Conclusions
A new series of curcumin–coumarin hybrid analogues 11–18 were synthesized
in low yield starting from 2′,2′-diphenyl-1,3-dioxol[h]coumarin-3-carbaldehyde (5), or
2′,2′-diphenyl-1,3-dioxol[g]coumarin-3-carbaldehyde (9), and the corresponding tris
(methoxymethoxy)benzaldehyde 10a–d. Synthesized derivatives did not reach a potential
as a multitarget drug. In general, they were either better at inhibiting MAO isoforms
or AChE and BuChE activity. Only compound 12 inhibited BuChE and MAO isoforms
with similar potency. In addition, compounds 14 and 16 resulted in being neuroprotective
against H2O2 in SH-SY5Y cells. The formulation of these compounds in nanoparticles
improves their neuroprotective activity at low concentrations. Results suggest that by
Molecules 2021, 26, 4550 14 of 16
modulating the substitution pattern on both coumarin moiety and phenyl ring, ChEs and
MAO-targeted derivatives or derivatives with activity in cell-based phenotypic assays can
be obtained.
Supplementary Materials: The following are available online. 1H and 13C NMR of compounds 5, 9,
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